Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25417329 | 1.00 | LMNA (0.32) | LMNACYP2C9 | |
| SCHEMBL2567708 | 0.97 | — | — | |
| SCHEMBL17338791 | 0.97 | — | — | |
| SCHEMBL17196020 | 0.97 | — | — | |
| SCHEMBL19976614 | 0.94 | LMNA (0.32) | LMNACYP2C9 | |
| SCHEMBL18769162 | 0.84 | — | — | |
| SCHEMBL14000270 | 0.82 | — | — | |
| SCHEMBL4096929 | 0.82 | — | — | |
| SCHEMBL14000168 | 0.82 | — | — | |
| SCHEMBL12918662 | 0.78 | MGAM (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| EP-2970259-B1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-12-21 | — | — | EP | disclosed |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-01-28 | — | — | US | disclosed |
| WO-2014140065-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | LMNA 3345/4885CYP2C9 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.